List of Yondelis drug patents
Yondelis is owned by Janssen Prods.
Yondelis contains Trabectedin.
Yondelis has a total of 2 drug patents out of which 0 drug patents have expired.
Yondelis was authorised for market use on 23 October, 2015.
Yondelis is available in powder;intravenous dosage forms.
The generics of Yondelis are possible to be released after 07 July, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895557 | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jan, 2028
(4 years from now) | |
|
US8895557
(Pediatric) | JANSSEN PRODS | Pharmaceutical formulations of ecteinascidin compounds |
Jul, 2028
(5 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 23, 2022 |
| Pediatric Exclusivity (PED) | Apr 23, 2023 |
Drugs and Companies using TRABECTEDIN ingredient
Market Authorisation Date: 23 October, 2015
Treatment: NA
Dosage: POWDER;INTRAVENOUS
YONDELIS family patents
3
United States
2
Argentina
2
Peru
2
China
1
Austria
1
Hong Kong
1
RS
1
Korea, Republic of
1
Brazil
1
Australia
1
Poland
1
Malaysia
1
Ukraine
1
Guatemala
1
Uruguay
1
Jordan
1
Spain
1
Germany
1
Israel
1
Cyprus
1
Mexico
1
Japan
1
Slovenia
1
United Kingdom
1
South Africa
1
Portugal
1
El Salvador
1
Russia
1
Croatia
1
Panama
1
Norway
1
New Zealand
1
Honduras
1
Canada
1
Taiwan, Province of China
1
Denmark
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic